2023 Fiscal Year Final Research Report
Development of novel efficacy-enhancing therapy for anticancer drugs via platelet activating factor receptor PAFR
| Project/Area Number |
22K20985
|
|---|
| Research Category |
Grant-in-Aid for Research Activity Start-up
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
0907:Oral science and related fields
|
|---|
| Research Institution | Chiba University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2022-08-31 – 2024-03-31
|
| Keywords | OSCC / PAFR / Ginkgolide B |
|---|
| Outline of Final Research Achievements |
Platelet activating factor (PAF), which is one of the exocrine factors of cells, is reported to affect an important role in the progression of cancer, however detailed studies have not yet been reported. In this study, we aimed to elucidate the mechanism of the malignant cycle in cancer caused by the autocrine action of PAF and the PAF receptor (PAFR). We confirmed the expression status of PAFR in oral squamous cell carcinoma-derived cell lines and human oral mucosal epithelial keratinocytes. Furthermore, we found that CDDP sensitivity was increased when using PAFR expression suppressed strains and the PAFR inhibitor Ginkgolide B in combination.
|
| Free Research Field |
口腔癌
|
| Academic Significance and Societal Importance of the Research Achievements |
口腔扁平上皮癌におけるCDDP感受性の調節にPAFRの関与が示唆された. さらにPAFR阻害剤であるGinkgolide Bの併用において, p-ERKおよびp-Aktの発現が抑制され化学療法抵抗性を克服し, CDDP治療の鍵となる可能性が考えられた. 化学療法において, 特にCDDPの副作用は大きな課題となっており, PAFRの阻害剤であるGinkgolide BがCDDP感受性を高めより低用量のCDDPで同等の効果を得ることができれば, 化学療法に有利に働くと考えられた. 本研究にて今後Ginkgolide B がCDDP併用療法の新規治療薬となる可能性が示唆された.
|
